-
3281
Presence of Brucella spp. in Milk and Dairy Products: A Comprehensive Review and Its Perspectives
Published 2023-01-01Get full text
Article -
3282
-
3283
-
3284
-
3285
-
3286
A Parallel Image Denoising Network Based on Nonparametric Attention and Multiscale Feature Fusion
Published 2025-01-01Get full text
Article -
3287
-
3288
-
3289
-
3290
-
3291
Primary Cognitive Factors Impaired after Glioma Surgery and Associated Brain Regions
Published 2020-01-01Get full text
Article -
3292
Crafting the Organic Mindset Through Attitude: A PLS-SEM Approach
Published 2024-12-01Get full text
Article -
3293
-
3294
-
3295
Effectiveness of PK-Guided Personalized Recombinant FVIII Treatment in Patients with Hemophilia A: Clinical Case Experiences Based on an Observational Study
Published 2025-01-01“…Yoko Mizoguchi,1 Moeko Hino,2 Hitoshi Ueda,3 Yasuo Miyaguchi,3 Masao Kobayashi1,4 1Department of Pediatrics, Hiroshima University Graduate School of Biomedical Sciences, Hiroshima, Japan; 2Department of Pediatrics, Chiba University Hospital, Chiba, Japan; 3Japan Medical Office, Takeda Pharmaceutical Company Limited, Tokyo, Japan; 4Japanese Red Cross, Chugoku-Shikoku Block Blood Center, Hiroshima, JapanCorrespondence: Yasuo Miyaguchi, Japan Medical Office, Takeda Pharmaceutical Company Limited, 2 Chome-1-1 Nihonbashihoncho, Chuo-ku, Tokyo, 103-0023, Japan, Tel +81 70-4921-7966, Email yasuo.miyaguchi1@takeda.comPurpose: Prophylaxis with recombinant factor VIII (rFVIII) products is the gold-standard treatment for hemophilia A. …”
Get full text
Article -
3296
Association Between Blood Pressure Variation During Dialysis and Cardio‐Cerebrovascular Events
Published 2025-01-01Get full text
Article -
3297
-
3298
-
3299
-
3300